QNRX
Quoin Pharmaceuticals, Ltd. (QNRX) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
QNRX provides no disclosed emissions, energy, or waste metrics in the supplied data, leaving its environmental positioning broadly opaque versus peers with more transparent reporting.
Zero reported R&D intensity limits evidence of process innovation that could reduce resource use, but this is not enough to distinguish it materially from peers.
The absence of capital-intensive leverage and the low net debt to EBITDA metric reduce near-term balance-sheet pressure, yet they do not directly evidence stronger environmental management than peers.
Without filing-based disclosure on climate targets, environmental incidents, or supply-chain controls, QNRX cannot be assessed as structurally advantaged on environmental risk versus peers.
Social
No disclosed workforce, safety, turnover, or diversity metrics are provided, so QNRX’s social performance remains difficult to compare against peers with fuller reporting.
Zero stock-based compensation to revenue suggests limited dilution-related employee incentive intensity, but it does not demonstrate stronger labor practices or retention versus peers.
The lack of customer, product-safety, and community-impact disclosures constrains visibility into reputational and regulatory social risks relative to peers.
Overall social positioning appears average to opaque because the available data show neither clear social strengths nor peer-level disclosure depth.
Governance
Zero debt to equity indicates a simple capital structure, which can reduce creditor complexity, but it does not by itself prove stronger governance than peers.
The low net debt to EBITDA metric suggests limited leverage-related governance pressure, yet peer comparison remains constrained without board, audit, or ownership disclosures.
No filing evidence is provided on board independence, executive compensation oversight, or shareholder rights, leaving core governance quality unverified versus peers.
Given the absence of controversy data and the limited financial-risk profile, QNRX appears neither structurally weak nor clearly superior on governance relative to peers.
Overall Score
QNRX’s ESG profile is best characterized as opaque and broadly average versus peers because the supplied data lack the disclosure depth needed to establish clear strengths.
Score Driver: Limited ESG Disclosure Across Environmental, Social, And Governance Dimensions Is The Decisive Factor Constraining Relative Positioning.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Quoin Pharmaceuticals, Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
